Mochi Health advertises compounded semaglutide "starting at $60" and compounded tirzepatide "starting at $90". Those are the numbers in the banner across the top of its site, marked down from $99 and $199. They are real prices for real products, and they are also two of the three numbers a prospective member needs. The third is on a different page.
Every figure here was read from Mochi's own pages on 2026-09-09. This page reports what the company publishes and what it costs. It does not say who should take a GLP-1 or at what strength; that belongs with a prescriber, as our editorial standards set out.
The arithmetic
Mochi's compounded semaglutide page states the price as "Starting at $60 + Mochi Health membership", and repeats underneath: "Requires a Mochi Health Membership. Cost of medication not included in Mochi Health Membership Fee."
The membership price is on the homepage, in a footnote under the hero:
The $39 promotional rate applies to your first month only for new customers. After that, the standard rate is $79 per month. Prepaid multi-month plans available. Terms vary by state.
So the two halves add up like this.
| Membership | Medication (lowest strength) | Total | |
|---|---|---|---|
| First month, compounded semaglutide | $39 | $60 | $99 |
| Standing month, compounded semaglutide | $79 | $60 | $139 |
| First month, compounded tirzepatide | $39 | $90 | $129 |
| Standing month, compounded tirzepatide | $79 | $90 | $169 |
The headline is $60. The lowest figure anyone pays in a standing month is $139, and that is with everything working in their favour — the cheaper of the two drugs, at the bottom of its strength ladder, after the introductory month has passed.
None of this is concealed. The membership requirement is printed directly beneath the price, in the same block, on the same page. But the number that travels — into search results, comparison articles and screenshots — is $60, and $60 is not what a month costs.
Price varies by strength, and the strengths are not the label's
Mochi states that "Price varies based on the dose your provider prescribes." The $60 and $90 figures therefore sit at the bottom of a ladder rather than in the middle of one.
The ladders themselves are worth setting down, because they answer a question that comes up whenever a compounded price is compared with a brand-name price: is this the same product more cheaply, or a different product?
| Strengths Mochi lists | Strengths on the approved label | |
|---|---|---|
| Semaglutide | 0.22 · 0.44 · 0.88 · 1.5 · 2.21 · 2.67 · 4.5 · 6.48 mg | 0.25 · 0.5 · 1 · 1.7 · 2.4 mg |
| Tirzepatide | 2.2 · 4.4 · 6.6 · 8.8 · 11.24 · 13.2 · 16.6 mg | 2.5 · 5 · 7.5 · 10 · 12.5 · 15 mg |
Not one number in the left column appears in the right column. They are close enough to look like the same ladder at a glance — 2.2 against 2.5, 4.4 against 5, 13.2 against 12.5 — and far enough apart that no strength Mochi sells is a strength any regulator has evaluated. The top of the compounded tirzepatide list, 16.6 mg, is above the top of the approved list at 15 mg.
That near-miss pattern is not an accident of manufacturing. Federal law restricts compounding a drug that is essentially a copy of a commercially available approved product, and a different strength is one of the ordinary ways a compounded preparation is distinguished from the approved one. The practical consequence for a reader is narrower and more useful than the legal background: a milligram figure on a compounded vial and the same-looking figure on an approved label are not interchangeable units, and a price per milligram calculated across the two is comparing quantities that were never defined the same way.
Mochi says as much itself, in the disclosure printed under the price: "Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality."
The testimonials are paid, and they say so
The compounded semaglutide page carries four member quotes — the kind of thing anyone searching for reviews of this company is looking for. Directly beneath them:
These are real Mochi members who were compensated for sharing their experiences.
This is the right disclosure to make and Mochi makes it clearly. It is reported here because of where the search traffic goes: a person looking up "Mochi Health reviews" lands on pages of testimonials, and the single line that separates a compensated endorsement from an ordinary one is set in the smallest type on the page. A paid testimonial is not a false one. It is a different kind of evidence, and the difference is only visible to someone who reads the footnote.
The same caution applies in the other direction. Aggregate star ratings for direct-to-consumer telehealth are gathered by companies with their own incentive structures, and a rating is not a measurement. We publish no score of our own for exactly this reason, which our editorial standards explain.
What Mochi does not make obvious
Three things, in descending order of how much they matter.
The membership is the product. Mochi sells across weight loss, hair loss, skincare, mental health, menopause and sexual health, and the $79 covers access and unlimited visits with the care team rather than the drug. That is a genuine offer — unlimited provider contact is not nothing, and it is more than most cash-pay routes include. It is simply not what the $60 refers to.
Mochi Health Corp. is not the prescriber. Its footer states that the company "provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself," and that clinical services come from "licensed physicians and clinicians affiliated with independently owned and operated professional practices." Nearly every US telehealth company is built this way, because most states bar corporations from owning medical practices. It is worth knowing only because the entity charging the card and the entity making the clinical decision are formally separate.
The 16% figure is self-reported. Mochi advertises an average first-year weight loss of 16% and qualifies it on the same page as "self reported", "provided for illustrative purposes only", "not guaranteed", and "not a medical prediction or guarantee of outcomes." Self-reported weight change from continuing members is not a trial result. The approved products' trial figures come from randomised studies with published protocols; there is no equivalent for any compounded preparation, because compounded preparations are not studied as products.
Who it appears to suit, and who it does not
On the published terms, the case for Mochi is a person paying cash, without coverage for a branded GLP-1, who values unlimited access to a care team and is willing to accept a preparation that has not been evaluated by a regulator, at a strength that does not correspond to any approved one.
The case against it is anyone who can reach a branded product. The manufacturers' own self-pay routes have moved a long way down in price — the current figures are on our GLP-1 cost page, and the brand-by-brand detail on what Zepbound costs and what Wegovy costs — and those are approved products with published labels and published trial data. A reader comparing $139 against $349 is comparing two different categories of thing, and the gap is smaller than it looks once the membership is added to one side and the approved status is added to the other.
The honest summary is that Mochi's pricing is clearly published and structurally split, and that almost all of the confusion around it comes from the split rather than from anything hidden. Both halves are on the site. They are just not on the same page.